FirmAtlas
Company handbook · KVUE · Prepared by FirmAtlas · firmatlas.app · printed 2026-10-16
KVUE · CIK 1944048 · LATEST FILING: 10-Q JUN '26 · FILED AUG 6, 2026
Kenvue Inc.
$18.91
+0.24 (+1.29%)
Close, Oct 16, 2026 · 52-week $14–20
Last fiscal year
Kenvue Inc. reported revenue of $15.1B for the year ended Dec 28, 2025 (FY25), down 2.1% from FY24. Net income was $1.5B, operating cash flow $2.2B and free cash flow $1.7B. Source: 10-K filed Feb 20, 2026.
Market cap
$36.2B
P/E
21.9
EV/EBITDA
12.1x
P/B
3.4
Div yield
5.52%
ROIC
17.9%
Revenue 1Y
−2.1%/yr
EPS 1Y
40.7%/yr
Shares 1Y
+0.1%
Loading chart…
Median
Daily closes, split-adjusted · ratios at each fiscal year end
Company
CEOKirk Perry
HQSummit, NJ
AuditorPricewaterhouseCoopers LLP
Employees22,000
Year endsJanuary
Revenue by segment · FY25
Self Care42%
Essential Health31%
Skin Health And Beauty27%
Compounded growth & averages
10Y
5Y
3Y
TTM
Share price
—
—
−1.1%
34.0%
Upgrade to see 10 years
Share price: yearly compound rate of the traded close; the last column is the past year.
Where the cash went · FY24–FY25
$4.5B deployed
Capex
$909M
20.3%
Dividends
$3.1B
70.0%
Buybacks
$432M
9.7%
Operating cash flow over the period: $4.0B. Total debt changed by −$100M. R&D of $790M is already inside operating costs.
More cash than debt at the end of FY25.
Growth engines
How much of the profit growth came from new investment, and how much from running the business better.
Upgrade to see 10 years
Financials
Last 2 years · Upgrade to see 10 years · USD millions · each year opens its 10-K · FY25 = year ended Dec 28, 2025 · change vs previous year
Last 4 quarters · USD millions · quarter-end month shown · change vs same quarter a year earlier
TTM = the last four quarters, to Jun '26. Balance-sheet rows show that latest quarter. “—” where the quarters do not add up to the annual figures. No TTM for cash: our quarterly rows do not hold short-term investments yet, and annual cash includes them.
Income
Revenue
15,455
15,124−2.1%
15,408
YoY
−2.1%
Gross profit
8,959
8,792−1.9%
8,966
Gross margin
58.0%
58.1%+0.2 pp
—
Operating income
1,841
2,414+31.1%
2,630
Operating margin
11.9%
16.0%+4.0 pp
—
EBITDA
2,463
2,971+20.6%
—
EBITDA margin
15.9%
19.6%+3.7 pp
—
Interest expense
431
430−0.2%
—
Interest coverage
5.71x
6.91x+1.19x
—
Net income
1,030
1,470+42.7%
1,658
YoY
+42.7%
Net margin
6.7%
9.7%+3.1 pp
—
EPS (diluted, $)
0.54
0.76+40.7%
0.87
YoY
+40.7%
Balance sheet
Total assets
25,601
27,076+5.8%
26,735
Cash & short-term investments
1,070
1,062−0.7%
—
Accounts receivable
2,165
2,382+10.0%
—
Inventory
1,591
1,666+4.7%
—
Net PP&E
1,849
2,212+19.6%
—
Other assets
18,926
19,754+4.4%
—
Total liabilities
15,933
16,311+2.4%
16,182
Accounts payable
2,254
2,473+9.7%
—
Total debt
800
700−12.5%
1,405
Other liabilities
12,879
13,138+2.0%
—
Shareholders’ equity
9,668
10,765+11.3%
10,553
Total liabilities = total assets − shareholders’ equity, so it includes minority interest where a company has one.
Cash flow statement · as filed
Cash from operations
1,769
2,197+24.2%
2,325
Net income
1,030
1,470+42.7%
—
Depreciation & amortization
622
557−10.5%
—
Stock-based compensation
254
136−46.5%
—
Working capital & other
(137)
34n/m
—
Cash from investing
(425)
(436)n/m
—
Capex
(434)
(475)n/m
—
Other investing
9
39+333.3%
—
Cash from financing
(1,565)
(1,837)n/m
—
Debt raised
0
746n/m
—
Debt repaid
0
(750)n/m
—
Dividends
(1,552)
(1,581)n/m
—
Buybacks
(235)
(197)n/m
—
Shares issued
95
122+28.4%
—
Other financing
127
(177)−239.4%
—
Net change in cash
(312)
(8)n/m
—
Free cash flow (OCF − capex)
1,335
1,722+29.0%
1,914
Where the cash went
Operating cash flow
1,769
2,197+24.2%
2,325
Reinvested in the business
434
475+9.4%
—
% of operating cash flow
24.5%
21.6%
Capex
434
475+9.4%
411
R&D (memo, already in costs)
408
382−6.4%
—
Free cash flow
1,335
1,722+29.0%
1,914
YoY
+29.0%
Returned to shareholders
1,787
1,778−0.5%
—
% of free cash flow
133.9%
103.3%
Dividends
1,552
1,581+1.9%
—
Buybacks
235
197−16.2%
—
Change in total debt
—
(100)
—
Cash left over
—
(156)
—
FCF conversion (FCF ÷ net income)
129.6%
117.1%−12.5 pp
—
Owner earnings
—
1,479
—
Owner earnings margin
—
9.8%
—
Buyback yield
0.6%
0.6%+0.0 pp
—
Returns & ratios
ROIC (all capital)
14.3%
17.9%+3.7 pp
—
ROIC (operating)
40.0%
49.7%+9.7 pp
—
Net debt / EBITDA
−0.11x
−0.12x−0.01x
—
Debt / equity
0.08x
0.07x−0.02x
—
Cash conversion cycle (days)
14
11−3 d
—
ROE
10.7%
13.7%+3.0 pp
—
ROA
4.0%
5.4%+1.4 pp
—
ROCE
9.3%
11.4%+2.2 pp
—
NOPAT
1,340
1,775+32.5%
—
Invested capital (operating)
3,351
3,787+13.0%
—
Invested capital (all)
9,398
10,403+10.7%
—
Reinvestment rate
—
24.6%
—
Debtor days
51
57+6 d
—
Inventory days
89
96+7 d
—
Days payable
127
143+16 d
—
Income
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
3,764
3,780
3,909
3,955
vs year-ago quarter
Gross profit
2,226
2,137
2,302
2,301
Gross margin
59.1%
56.5%
58.9%
58.2%
Operating income
629
535
767
699
Net income
398
330
474
456
vs year-ago quarter
Net margin
10.6%
8.7%
12.1%
11.5%
EPS (diluted, $)
0.21
0.17
0.25
0.24
vs year-ago quarter
Balance sheet
Sep '25
Dec '25
Mar '26
Jun '26
Total assets
27,248
27,076
26,854
26,735
Cash & equivalents
1,139
1,062
1,075
1,110
Total debt
1,160
700
1,586
1,405
Shareholders’ equity
10,634
10,765
10,608
10,553
Cash flow
Sep '25
Dec '25
Mar '26
Jun '26
Operating cash flow
294
854
489
688
Capex
98
110
139
64
Free cash flow
196
744
350
624
vs year-ago quarter